Activation of resident memory t cells for cancer immunotherapy
AssigneeNew York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
InventorsDavid B. Masopust, Jr., Vaiva D. Vezys
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
Claims21
(canceled)
An article of manufacture comprising:
- at least one antigenic peptide from a first microorganism in a pharmaceutically acceptable carrier, wherein the first microorganism is EBV.
An article of manufacture comprising:
- at least one antigenic peptide from a first microorganism in a pharmaceutically acceptable carrier, wherein the first microorganism is CMV.
An article of manufacture comprising:
- an adjuvant consisting essentially of an antigenic peptide from a first microorganism in a pharmaceutically acceptable carrier, wherein the first microorganism is EBV.
A method of increasing the efficacy of immunotherapy in an individual, comprising administering an adjuvant to a solid tumor to activate resident memory T cells, wherein the adjuvant comprises at least one antigenic peptide from EBV, thereby increasing the efficacy of the immunotherapy in the individual.
Dependencies are inferred from the claim text.